The ITALIC StudyIs There A LIfe for DES after discontinuation of Clopidogrel : The ITALIC Study - ITALIC

French Society of Cardiology0 个研究点开始时间: 2008年8月4日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•- Male or female subject =18 years of age eligible for PCI with at least one DES Xience implanted in all clinical situations excluding primary PCI for acute MI and treatment of the left main artery.
•- Male or female subject =18 years of age eligible for PCI with at least one DES Xience.
•- Patient not pre-treated with abxicimab or eptifibatide during hospitalization
•- Patient pre-treated with aspirin and clopidogrel before PCI
•- ASA check at least 24 hours after the interruption of tirofiban
•- The subject has given written informed and dated consent to participate in this study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- Subjects not able to give informed consent
•- Known platelets< 100 000/µl or known hemorrhagic diathesis
•- Oral anticoagulation or treatment with abxicimab or eptifibatide during hospitalization
•- ASA check less than 24 hours after the interruption of tirofiban
•- Thrombolytic therapy within 4 days before ASA check
•- Contra-indication to aspirin or clopidogrel
•- Recent major surgery <6 weeks
•- Evidence of an active gastrointestinal or urogenital bleeding
•- Severe liver insufficiency
•- Primary PCI for acute MI
•- Left main PCI
•- Any scheduled surgery during the year after enrolment
•- Severe concomitant disease with life expectation < two years

发起方

French Society of Cardiology